Archive ouverte HAL - Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease

Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease

L. Rostaing 1, 2 M. Heitz 1, 2 P. Carron 1 G. Clavarino 3, 4, 2 T. Jouve 1, 2 N. Pinel 5 F. Guebre-Egziabher 1, 2
3 TIMC-IMAG-BNI - Barrière Naturelle et Infectiosité
TIMC-IMAG - Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525
Abstract : Anti-glomerular basement-membrane (anti-GBM) disease (or Goodpasture disease) is characterized by severe kidney and lung involvement. Prognoses have improved with treatments that combine plasma exchange and immunosuppressive drugs. However, patients with severe renal involvement can have poor renal outcomes and cyclophosphamide can cause significant complications. Anti-GBM antibodies have a direct pathogenic effect on the disease: thus, therapeutics that can decrease their production, such as rituximab, could be a good alternative.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-02180322
Contributeur : Cordelia Bisanz <>
Soumis le : jeudi 11 juillet 2019 - 13:46:51
Dernière modification le : vendredi 12 juillet 2019 - 01:15:41

Lien texte intégral

Identifiants

Collections

Citation

L. Rostaing, M. Heitz, P. Carron, G. Clavarino, T. Jouve, et al.. Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease. BMC Nephrology, BioMed Central, 2018, 19 (1), pp.241. ⟨10.1186/s12882-018-1038-7⟩. ⟨hal-02180322⟩

Partager

Métriques

Consultations de la notice

20